- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01408277
Using Santyl on Diabetic Foot Ulcers
A Comparison of Collagenase Santyl® Ointment Used Adjunctively to Sharp Surgical Debridement and Sharp Surgical Debridement in the Care of Diabetic Foot Wounds
Subjects enrolled in this study will either use Santyl daily or follow standard care procedures for up to 6 weeks for their diabetic foot wound. After 6 weeks of treatment, the subjects will continue into the follow-up phase for an additional 6 weeks. Study doctors will look at the wound in the office each week (up to 12 weeks) to see if the wound is healing. Depending on a number of factors at each office visit, the study doctors may also use a procedure called sharp debridement to remove dead skin from the wound.
This study will test the hypothesis that daily treatment of diabetic foot wounds with Santyl will result in more rapid healing, healthier wounds, and fewer required sharp debridements over the study period than for diabetic foot wounds treated in other ways.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85015
- Associated Foot and Ankle Specialists
-
Tucson, Arizona, United States, 85710
- Aung Foothealth Clinics
-
-
Michigan
-
Southfield, Michigan, United States, 48076
- Foot Healthcare Associates, PC
-
-
New Jersey
-
Summit, New Jersey, United States, 07901
- Overlook Hospital Wound Care Center
-
-
Texas
-
Fort Worth, Texas, United States, 76107
- UNTHSC Fort Worth
-
San Antonio, Texas, United States, 78229
- Endeavor Clinical Trials
-
San Antonio, Texas, United States, 78212
- Robert Wunderlich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
- Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
- Subjects 18 years of age or older. Subjects may be of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
- A target ulcer which is 0.5 cm2 - 10 cm2 inclusive (as measured at the Screening Visit) with a duration ≥ 30 days (documented in the patient's history or by patient report of onset) which requires sharp surgical debridement.
- Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.7 and ≤ 1.1. If the ABI is greater than 1.1, then a toe pressure of > 40 mmHg OR a TcPO2 ≥ 40 mmHg must be present. Either toe pressure or TcPO2 is also acceptable as a stand-alone measurement, but if both are obtained, each must meet its respective cutoff.
- Alternatively, a Doppler waveform consistent with adequate flow to the region of the foot with the target ulcer (biphasic or triphasic waveforms) is acceptable.
- A target ulcer that is not infected based on clinical assessment.
- Willing and able to make all required study visits.
- Able to follow instructions and perform the dressing changes at home or have a caregiver who can perform the dressing changes according to the protocol.
- Willing to use an appropriate off-loading device whenever necessary to keep weight off of any foot ulcers.
- History of diabetes mellitus (Type 1 or 2) requiring insulin or oral hypoglycemic medications to control blood glucose levels.
CBC and blood chemistry values as follows:
- Serum albumin ≥ 2.0 g/dL
- Pre-albumin levels of ≥ 15 mg/dL
- Alkaline phosphatase ≤ 500 U/L
- Alanine aminotransferase (ALT) ≤ 200 U/L
- Aspartate aminotransferase (AST) ≤ 175 U/L
- Serum total bilirubin ≤ 3.0 mg/dL
- Serum BUN < 75 mg/dL
- Serum creatinine ≤ 4.5 mg/dL
- HbA1c ≤ 12%
- Hemoglobin (Hgb) > 8.0 g/dL
- WBC > 2.0 x 109/L
- Absolute neutrophil count > 1.0 x 109/L
- Platelet count > 50 x 109/L
EXCLUSION CRITERIA
- Contraindications or hypersensitivity to the use of the study medications or their components.
- Target ulcer does not require debridement.
- Uncontrolled bleeding disorder.
- Cellulitis of the target wound, lymphangitic streaking, deep tissue abscess, gangrene, or infection of muscle, tendon, joint or bone.
- Infection with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, azotemia).
Any of the following:
- Target ulcer tunneling
- Target ulcer requires hyperbaric or negative pressure therapy per the investigator's medical judgment
- Target ulcer is on the heel and cannot be offloaded
- Target ulcer is over a Charcot deformity which cannot be offloaded
- NOTE: A heel ulcer or an ulcer over a Charcot is not excluded unless effective offloading is not possible.
- Current, ongoing osteomyelitis of the target foot as determined by medical history.
- Participation in another investigational clinical study within thirty (30) days of the Screening Visit.
- A target ulcer which involves underlying tissues (i.e., fat, fascia, tendon, muscle, bone).
- A target ulcer on a non-neuropathic foot (neuropathic defined as inability to perceive 10 grams pressure using a Semmes-Weinstein 5.07 or equivalent monofilament in the periwound area).
- NOTE: Monofilament test result must be documented.
- Diagnosis of chronic granulomatous disease, leukocyte adhesion defects, or severe neutropenia.
Current treatment (at the time of the Screening Visit) with any of the following:
- Systemic corticosteroids
- Immunosuppressive agents
- Chemotherapeutic agents
- Antiviral agents
- Platelet-derived growth factor (e.g., Regranex)
- Living skin equivalent (e.g., Apligraf)
- Dermal substitute (e.g., Dermagraft, Integra, etc.)
- Systemic antibiotic therapy or topical antibiotic treatment of the target ulcer
- Radiation therapy to the target lower extremity within 30 days prior to screening The Medical Monitor and/or Investigator may declare any subject ineligible for a valid medical reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Santyl
2mm Santyl applied once daily.
|
2 mm Santyl applied once daily
|
ACTIVE_COMPARATOR: Control
Standard Care
|
Standard Care
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Change in Wound Area
Time Frame: 6 and 12 weeks
|
Wound area was measured using the ARANZ Silhouette digital wound imaging and measurement device.
The average percent (%) of change from baseline of the target wound area at the end of the 6-week treatment period and the end of the entire 12-week study period respectively, was calculated using a two-way ANCOVA model.
|
6 and 12 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 017-101-09-030
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcers
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatedDiabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg UlcersUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers (DFU) | Venous Stasis Ulcers (VSU)United States
-
Oneness Biotech Co., Ltd.Completed
-
Hadassah Medical OrganizationUnknown
-
Systagenix Wound ManagementUnknownDiabetic Foot UlcersItaly, United States, United Kingdom, Germany, Spain
-
Southern California Institute for Research and...Heritage Medical Research InstituteUnknownDiabetic Foot UlcersUnited States
Clinical Trials on Santyl
-
HealthpointCompleted
-
HealthpointCompletedFollow up to Acute Wound Scar StudyUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Foot WoundsUnited States
-
Smith & Nephew, Inc.WithdrawnPressure Ulcer | Foot Ulcer, DiabeticUnited States
-
HealthpointCompletedDiabetic Foot UlcersUnited States
-
Integra LifeSciences CorporationTerminated
-
Smith & Nephew, Inc.Terminated
-
Smith & Nephew, Inc.Completed
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States, Canada